It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
Engaged in fighting the COVID-19 pandemic? Need fast antibody generation for diagnostic or therapeutic applications? Try our LiAb-SFCOVID-19™ library and antibody phage display services for therapeutic applications to get high-affinity human antibodies in less than 2 months.
It is urgent to implement efficient diagnostic and therapeutic solutions. We generate your high-affinity antibodies in 7 weeks.
Save time and money by choosing your antigen in our catalog of ready-to-use COVID-19 antigens.
No need for further humanization! Save several months of engineering.
Maximize your chance to generate high affinity anti SARS-CoV-2 antibodies.
The huge diversity of our library is your guarantee to generate high affinity antibodies.
We are so confident in the quality of our library that we guarantee that we will identify at least 3 binders against your antigen.
The perfect solution for the development of antibody cocktails!
You want to screen our library in your own lab? Buy our COVID-19 library!
The COVID-19 pandemic caused a global health emergency necessitating a strong cooperation between all the health and life science community to combine their core expertise for the development of diagnostic and therapeutic solutions. ProteoGenix contributes to this global effort with the development of a new COVID-19 immune human library: LiAb-SFCOVID-19™. Our mission is to share our expertise in antibody generation with the scientific community to allow them accelerating the development of fast and reliable immunoassays as well as efficient therapies.
Detects the genetic presence of SARS-CoV-2 through nucleic acid testing. Highly accurate, but too slow to run at high volume.
A rapid lateral flow test already widely used for influenza. Fast enough for mass testing, but historically limited by low sensitivity.
The primary antibody on the membrane recognizes virus particles in the patient’s mucus sample.
A chemically modified secondary antibody binds the captured virus, making its presence detectable.
Several strategies have been employed to try to mitigate the COVID-19 pandemic. This includes:
Even if this latest strategy demonstrated promising results, it suffers from various limitations such as low reproducibility (due to batch-to-batch variations) or the risk of transmitting blood-borne infections. One alternative strategy to overcome these limitations would be the development of neutralizing monoclonal antibody therapies which can be easily produced in large quantities and in a reproducible manner.
The development of highly efficient antibody therapies depends on the capacity of determining the right target. Previous studies demonstrated that two proteins of the coronavirus particles were particularly interesting for the development of neutralizing antibodies, namely the spike protein (S protein) and the nucleocapsid protein (N protein). Up to now, most of the therapeutic antibodies developed focused on the spike protein (S protein), a homotrimeric protein anchored in the viral membrane. Each monomer is composed of two subunits S1 and S2. S1 contains the N-terminal domain and the receptor binding domain (RBD)responsible for the attachment with human Angiotensin converting receptor 2 (ACE2) whereas S2 exposes a viral fusion peptide. Most of the therapeutic antibodies currently tested in clinical trials are neutralizing antibodies (nAbs) targeting epitopes from the RBD domain of the Spike protein. It was also discovered that the targeting of the N-terminal domain of the Spike protein of SARS-CoV-2, located on the S1 subunit, could also lead to the development of promising neutralizing antibodies.
Looking for ready-to-use antigens to generate your anti-SARS-CoV-2 antibodies? Get them in 1 week thanks to our COVID-19 proteins and peptides catalog.
The rapid emergence of escape mutants was one of the main problems observed for SARS-CoV and MERS. The lessons learned from these previous coronaviruses forced scientists to anticipate this hypothesis. Two solutions are mainly used to avoid escape mutants:
Target highly conserved epitopes or
Produce neutralizing antibody cocktails targeting simultaneously non-RBD and RBD epitopes.
Develop antibodies against several antigens in less than 2 months
Get high-affinity human antibodies
Need more information? Contact your account manager!
